Begin main content


Last Updated: November 11, 2019
Result type: Reports
Project Number: SR0634-000
Product Line: Common Drug Review

Generic Name: budesonide

Brand Name: Jorveza

Manufacturer: AVIR Pharma Inc.

Indications: Eosinophilic esophagitis, adults

Manufacturer Requested Reimbursement Criteria1: For the induction of clinico-pathological remission in adults with eosinophilic esophagitis (EoE), as per Health Canada indication

Submission Type: New

Project Status: Received

Companion Diagnostics: No

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input postedSeptember 03, 2019
Patient group input closedOctober 23, 2019

- Patient input submission received from AEDESEO, American Partnership for Eosinophilic Disorders, ausEE Inc., CURED foundation, Gastrointestinal Society and FABED Families Affected by Eosinophilic Disorder

Patient input summary sent for review to patient input groups-
Patient group comments on input summary closed-
Submission receivedNovember 08, 2019
Submission accepted for reviewNovember 22, 2019
Review initiated-
Draft CADTH review report(s) sent to sponsor-
Comments from sponsor on draft CADTH review report(s) received-
CADTH review team's comments on draft CADTH review report(s) sent to sponsor-
Canadian Drug Expert Committee (CDEC) meeting-
CDEC recommendation sent to sponsor and drug plans-